Tirzepatide for Alcohol Use Disorder

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of Southern California
Study ID
NCT06994338
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Tirzepatide injections (2.5mg, 5.0mg)
  • Placebo injections — DRUG
    Placebo injections

Study Details

The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.

Key Dates

Start date
Oct 6, 2025
Status verified
Oct 2025
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
42 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Tirzepatide
  • Placebo Comparator: Placebo

Primary Outcome Measure

Number of heavy drinking days [ Time Frame: Last 4 weeks of treatment (Weeks 5-8) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Keck School of Medicine, University of Southern CaliforniaLos AngelesCalifornia90032
Tom Gilmore
[email protected]
2139620698

Find similar trials in Los Angeles, CA

By condition
Substance use disorder
By specialty
Behavioral healthAddiction medicine
By research site
Keck School of Medicine, University of Southern California· Los Angeles, CA

Related Studies